Market Overview

A Peek Into The Market Before The Trading Starts

A Peek Into The Market Before The Trading Starts
Related RUE
Benzinga's M&A Chatter for Thursday October 10, 2013
rue21 Announces Funds Advised by Apax Close Purchase
Related ACTG
Acacia Research Owns More In Veritone Than Its Own Market Cap
20 Biggest Mid-Day Losers For Wednesday

Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average gained 12 points to 13,168.00 and S&P 500 index futures rose 3.50 points to 1,413.30. Nasdaq 100 futures climbed 15 points to 2,790.00.

A Peek Into Global Markets European markets were mostly higher today. The STOXX Europe 600 Index rose 0.12%, French CAC 40 Index rose 0.12% and German DAX 30 index gained 0.24%.

Asian markets ended mostly lower, with Japan's Nikkei Stock Average rising 0.16%, China's Shanghai Composite falling 1.74% and Australia's S&P/ASX 200 dropping 0.08%. Hong Kong's Hang Seng Index declined 0.41% and India's Sensex fell 0.59%.

Broker Recommendation Analysts at Jefferies upgraded rue21 (NASDAQ: RUE) from “hold” to “buy.” The target price for rue21 has been raised from $32 to $40.

rue21 shares dropped 6.89% to close at $26.88 on Friday.

Breaking news

  • Acacia Research (NASDAQ: ACTG) announced today that its subsidiaries including Advanced Data Access LLC and Smart Memory Solutions LLC entered into an agreement with Fujitsu Semiconductor America, Inc. and Fujitsu Semiconductor Limited. To read the full news, click here.
  • European regulators have approved an expanded indication for the Boston Scientific (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device. To read the full news, click here.
  • Trimble (NASDAQ: TRMB) announced today that it has entered into a definitive agreement to acquire privately-held TMW Systems, Inc., a leading provider of enterprise software to transportation and logistics (T&L) companies. To read the full news, click here.
  • ImmunoGen (NASDAQ: IMGN) today announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a significant improvement in OS compared to those randomized to standard-of-care therapy. To read the full news, click here.

Posted-In: Jefferies US Stock FuturesNews Futures Global Pre-Market Outlook Markets


Related Articles (ACTG + BSX)

View Comments and Join the Discussion!